why GenMark Diagnostics Inc. [GNMK] is a Good Choice for Investors After New Price Target of $23.03

GenMark Diagnostics Inc. [NASDAQ: GNMK] stock went on a downward path that fall over 0.00% on Thursday, amounting to a one-week price increase of more than 0.17%. The company report on April 13, 2021 that INVESTIGATION ALERT: Halper Sadeh LLP Investigates LMNX, NUAN, CADE, GNMK; Shareholders are Encouraged to Contact the Firm.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:.

Luminex Corporation (NASDAQ: LMNX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to DiaSorin S.p.A. for $37.00 per share. If you are a Luminex shareholder, click here to learn more about your rights and options.

Over the last 12 months, GNMK stock rose by 233.19%. The one-year GenMark Diagnostics Inc. stock forecast points to a potential downside of -4.17. The average equity rating for GNMK stock is currently 3.00, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $1.76 billion, with 71.81 million shares outstanding and 68.45 million shares in the current float. Compared to the average trading volume of 2.97M shares, GNMK stock reached a trading volume of 3248388 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on GenMark Diagnostics Inc. [GNMK]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GNMK shares is $23.03 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GNMK stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Needham have made an estimate for GenMark Diagnostics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 05, 2020. While these analysts kept the previous recommendation, Needham raised their target price from $15 to $19. The new note on the price target was released on July 08, 2020, representing the official price target for GenMark Diagnostics Inc. stock. Previously, the target price had yet another raise from $11 to $15, while Needham kept a Buy rating on GNMK stock.

The Average True Range (ATR) for GenMark Diagnostics Inc. is set at 0.51, with the Price to Sales ratio for GNMK stock in the period of the last 12 months amounting to 10.27. The Price to Book ratio for the last quarter was 18.31, with the Price to Cash per share for the same quarter was set at 1.74.

GNMK Stock Performance Analysis:

GenMark Diagnostics Inc. [GNMK] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.17. With this latest performance, GNMK shares gained by 0.38% in over the last four-week period, additionally plugging by 94.57% over the last 6 months – not to mention a rise of 233.19% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GNMK stock in for the last two-week period is set at 66.15, with the RSI for the last a single of trading hit 65.38, and the three-weeks RSI is set at 65.50 for GenMark Diagnostics Inc. [GNMK]. The present Moving Average for the last 50 days of trading for this stock 21.23, while it was recorded at 23.97 for the last single week of trading, and 16.07 for the last 200 days.

Insight into GenMark Diagnostics Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and GenMark Diagnostics Inc. [GNMK] shares currently have an operating margin of -6.44 and a Gross Margin at +39.61. GenMark Diagnostics Inc.’s Net Margin is presently recorded at -10.87.

Return on Total Capital for GNMK is now -8.18, given the latest momentum, and Return on Invested Capital for the company is -14.05. Return on Equity for this stock declined to -35.06, with Return on Assets sitting at -11.13. When it comes to the capital structure of this company, GenMark Diagnostics Inc. [GNMK] has a Total Debt to Total Equity ratio set at 92.51. Additionally, GNMK Total Debt to Total Capital is recorded at 48.05, with Total Debt to Total Assets ending up at 38.98. Long-Term Debt to Equity for the company is recorded at 89.22, with the Long-Term Debt to Total Capital now at 46.35.

Reflecting on the efficiency of the workforce at the company, GenMark Diagnostics Inc. [GNMK] managed to generate an average of -$30,168 per employee. Receivables Turnover for the company is 9.14 with a Total Asset Turnover recorded at a value of 1.02.GenMark Diagnostics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.40 and a Current Ratio set at 3.90.


With the latest financial reports released by the company, GenMark Diagnostics Inc. posted -0.12/share EPS, while the average EPS was predicted by analysts to be reported at -0.14/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 14.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GNMK.

GenMark Diagnostics Inc. [GNMK] Insider Position Details

There are presently around $1,748 million, in the hands of institutional investors. The top three institutional holders of GNMK stocks are: FMR LLC with ownership of 10,758,659, which is approximately 0.919% of the company’s market cap and around 4.30% of the total institutional ownership; WASATCH ADVISORS INC, holding 6,672,180 shares of the stock with an approximate value of $160.07 million in GNMK stocks shares; and BLACKROCK INC., currently with $134.91 million in GNMK stock with ownership of nearly 4.904% of the company’s market capitalization.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Positions in GenMark Diagnostics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 75 institutional holders increased their position in GenMark Diagnostics Inc. [NASDAQ:GNMK] by around 12,236,342 shares. Additionally, 89 investors decreased positions by around 8,871,547 shares, while 22 investors held positions by with 51,772,144 shares. The mentioned changes placed institutional holdings at 72,880,033 shares, according to the latest SEC report filing. GNMK stock had 27 new institutional investments in for a total of 2,668,062 shares, while 38 institutional investors sold positions of 2,166,410 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam